Hill-Rom Holdings hit an unexpected obstacle in its path from hospital bed-maker to digital medical device and analytics company., Modern Healthcare reports. The Delaware Court of Chancery won’t let Chicago-based Hill-Rom, which now goes by Hillrom, out of its $375 million deal to buy Bardy Diagnostics, despite Medicare’s decision to significantly cut payments for Bardy’s wearable cardiac monitor. Hillrom intends to appeal the ruling, but the episode underscores the perils of acquisitions in an industry that’s heavily dependent on the public and private insurers that pay for medical products and services in the U.S. Read more.
Medicare Scrambles Hillrom’s Digital Dealmaking: Report
